Prothena Corporation plc (LON:0Y3M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 350.38M +13.9% |
| Revenue (ttm) | 41.10M +427.3% |
| Net Income | -33.16M |
| EPS | -0.63 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 316 |
| Open | 9.16 |
| Previous Close | 8.73 |
| Day's Range | 8.90 - 9.16 |
| 52-Week Range | 7.46 - 11.67 |
| Beta | -0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Prothena Corporation
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau a... [Read more]
Financial Performance
In 2025, Prothena Corporation's revenue was $9.68 million, a decrease of -92.83% compared to the previous year's $135.16 million. Losses were -$244.09 million, 99.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.
Prothena Corporation Earnings release: Q2 2026
Prothena Corporation released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Prothena Corporation Quarterly report: Q2 2026
Prothena Corporation has published its Q2 2026 quarterly earnings report on August 6, 2026.
Prothena Corporation Slides: Corporate presentation
Prothena Corporation has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Prothena to Report Second Quarter 2026 Financial Results on August 6
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena will report its second quarter and first six months of 2026 financial results on August 6, 2026.
Prothena price target raised to $20 from $19 at Citizens
Citizens raised the firm’s price target on Prothena (PRTA) to $20 from $19 and keeps an Outperform rating on the shares. Prothena’s Q1 update highlighted continued advancement of partnered and…
Prothena cuts FY26 net cash used view to $18M-$23M from $50M-$55M
Prothena (PRTA) is updating its projected full year 2026 net cash used in operating and investing actives, and expects it to be $18 to $23 million (versus prior guidance $50…
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
Prothena Corporation Earnings release: Q1 2026
Prothena Corporation released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Prothena Corporation Quarterly report: Q1 2026
Prothena Corporation has published its Q1 2026 quarterly earnings report on May 7, 2026.
Prothena Corporation Slides: Corporate presentation
Prothena Corporation has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Prothena to Report First Quarter 2026 Financial Results on May 7
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after close of the U.S. financial markets.
Prothena announces Novo Nordisk obtained FDA fast track for PRX004
The company states: “Prothena (PRTA) announced that the FDA has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter antibody currently in Phase 3 development for th...
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
Prothena names Annie Kingston as Chief Strategy Officer
Prothena (PRTA) announced updates to its leadership team. Annie Kingston is being promoted to Chief Strategy Officer and Michael Isaacs is being promoted to General Counsel and Corporate Secretary. Is...
Prothena Announces Leadership Team Updates
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
Prothena Corporation Proxy statement: Proxy filing
Prothena Corporation filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Prothena Corporation Proxy statement: Proxy filing
Prothena Corporation filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.
Prothena Corporation Transcript: The Citizens Life Sciences Conference 2026
The company highlighted its robust pipeline in neurodegenerative and protein misfolding diseases, with major partnered programs advancing in phase III and significant milestone payments expected this year. CYTOPE technology was showcased as a novel platform for targeting intracellular proteins, with further updates anticipated in 2024.
Prothena achieves $50M clinical milestone payment from Novo Nordisk
The company states: “Prothena (PRTA) announced that the Company earned a $50 million milestone payment from Novo Nordisk (NVO) related to the achievement of a prespecified enrollment target in the…
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.
Prothena Corporation Slides: Corporate presentation
Prothena Corporation has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Prothena announces $100M share repurchase plan
Prothena (PRTA) announced that its Board of Directors has authorized a Share Repurchase Plan under which the company may repurchase up to $100M of the company’s outstanding ordinary shares. Published…
Prothena expects to end year with $255M in cash, equivalents
Prothena (PRTA) had cash, cash equivalents and restricted cash of $308.4M and no debt as of December 31, 2025. Excluding any potential purchases under its share repurchase plan, Prothena expects…